Edd Fleming
Executive Vice President, Commercialization @ Enavate Sciences
Palo Alto, United States
Edd Fleming is a Series B investor at Enavate Sciences in Palo Alto focused on Health Care and Medical. Edd Fleming is the Executive Vice President, Commercialization of Enavate Sciences. He previously worked at McKinsey & Company as a Senior Partner. Edd Fleming attended Harvard University.
- Total investments:
- 6
- Last investment:
- Lead investor:
- 83%
Last updated:
For AI agents: llms.txt
Industries Edd Fleming invests in
Stages Edd Fleming invests in
Countries Edd Fleming invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 3 (50%)
- Medical 2 (33%)
- Biopharma 2 (33%)
- Pharmaceutical 2 (33%)
- Genetics 1 (17%)
Stage
- Series B 3 (50%)
- Series A 1 (17%)
- Series C 1 (17%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| OrsoBio is a clinical-stage biopharmaceutical company that creates therapies for patients suffering from severe metabolic disorders such as diabetes, severe dyslipidemia, lipodystrophies, and others. OrsoBio is committed to restoring energy homeostasis in patients with severe metabolic disorders, in some cases, by targeting pathways relevant tomaintaining energy balance. OrsoBio revolutionizes the treatment of these disorders by addressing the underlying cause. | $67M / Series B / Sep 06, 2024 | ||
| Sionna Therapeutics is developing novel small molecule therapies to treat cystic fibrosis (CF). | $182M / Series C / Mar 06, 2024 | ||
| Sudo Biosciences is a biopharmaceutical company committed to developing cutting-edge medications that are unmatched in their class. | $30M / Series B / Feb 13, 2024 | ||
| Sudo Biosciences is a biopharmaceutical company committed to developing cutting-edge medications that are unmatched in their class. | $116M / Series B / Dec 20, 2023 | ||
| OrsoBio is a clinical-stage biopharmaceutical company that creates therapies for patients suffering from severe metabolic disorders such as diabetes, severe dyslipidemia, lipodystrophies, and others. OrsoBio is committed to restoring energy homeostasis in patients with severe metabolic disorders, in some cases, by targeting pathways relevant tomaintaining energy balance. OrsoBio revolutionizes the treatment of these disorders by addressing the underlying cause. | $60M / Series A / Nov 07, 2023 | ||
| Upstream Bio focuses on developing an antibody therapy for the treatment of severe asthma. They are clinical-stage monoclonal antibodies that inhibit the TSLP receptor, a validated target located upstream of various signaling cascades that influence a range of immune cells that are important in common and unusual illnesses. | $200M / Series B / Jun 08, 2023 |
Co-Investors
About Enavate Sciences
Enavate Sciences is committed to investing in and supporting the strategic growth of innovative therapeutic and enabling technology companies.
Enavate Sciences Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Christine Del Corsano
Chief Financial Officer
|
|||
|
Edd Fleming
Executive Vice President, Commercialization
|
|||
James Boylan
Chief Executive Officer
|
|||
Robert Glassman
EVP, Search and Evaluation
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Edd Fleming invest in?
Edd Fleming invests primarily in Health Care, Medical and Biopharma startups, most often at Series B and Series A stage. Most of the 6 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Edd Fleming?
Public channels for Edd Fleming include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Edd Fleming last invest?
The most recent investment recorded for Edd Fleming closed in Sep 2024. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
